Form 4: Verona Pharma Director Sells All Shares in Merger

Verona Pharma director Martin Edwards divests all holdings, including shares, RSUs, and options, following the company's acquisition by Merck Sharp & Dohme LLC.

Summary

• Martin Edwards, a Director of Verona Pharma plc, reported changes in his beneficial ownership due to the company's acquisition.
• The transactions occurred on October 7, 2025, as a result of a Scheme of Arrangement under the UK Companies Act 2006.
• Verona Pharma plc is being acquired by Merck Sharp & Dohme LLC (Parent) and Vol Holdings LLC (Bidco) pursuant to a Transaction Agreement dated July 8, 2025.
• Edwards disposed of 157,992 Ordinary Shares as part of the Scheme of Arrangement.
• 72,000 Restricted Share Units (RSUs), representing ADSs, were fully vested and converted into cash.
• Multiple tranches of share options, totaling 620,000 options, were fully vested and converted into cash if their exercise price was less than the ADS consideration.
• Following these reported transactions, Edwards holds 0 Ordinary Shares and 0 derivative securities in Verona Pharma plc.
• Each Ordinary Share was converted into the right to receive $13.375 in cash, and each ADS (representing eight Ordinary Shares) was converted into $107 in cash.

Sentiment

Score: 8

Explanation: The filing reports the successful completion of an acquisition, resulting in the director receiving cash for all his equity holdings. This indicates a positive outcome for the reporting person and the company's shareholders who participated in the Scheme of Arrangement.

Positives

• Director Martin Edwards received cash for all his equity holdings in Verona Pharma plc, including Ordinary Shares, Restricted Share Units, and Share Options.
• The company is being acquired by Merck Sharp & Dohme LLC, providing a clear exit strategy and value realization for shareholders.
• Restricted Share Unit awards and share options were fully vested and converted into cash, benefiting the holder.

Negatives

• Verona Pharma plc will no longer be an independent publicly traded entity following the acquisition.

Risks

• No specific risks related to the company's operations or future outlook are detailed in this Form 4, as it primarily reports the outcome of an acquisition.

Future Outlook

Verona Pharma plc is undergoing an acquisition by Merck Sharp & Dohme LLC, which will result in it no longer being an independent publicly traded entity. Its future operations will be integrated into the acquiring company.

Management Comments

• No direct quotes from company management are provided in this Form 4, which reports the execution of a pre-arranged transaction.

Industry Context

The acquisition of Verona Pharma plc by Merck Sharp & Dohme LLC is consistent with broader industry trends of larger pharmaceutical companies acquiring smaller biotech firms to expand their pipelines and intellectual property. This often occurs after significant clinical milestones or regulatory progress, providing an exit for early investors and founders.

Comparison to Industry Standards

• The cash consideration of $13.375 per Ordinary Share and $107 per ADS represents the agreed-upon value in the acquisition. This valuation would typically be benchmarked against the company's trading price prior to the announcement and valuations of comparable M&A transactions in the biopharmaceutical sector. Specific comparable companies or projects are not detailed in this filing.

Management Changes

Corporate Governance

Legal Proceedings

• The transactions are executed pursuant to a 'Scheme of Arrangement' under Part 26 of the UK Companies Act 2006, which is a formal legal process for corporate restructuring or acquisition.

Related Party Transactions

• No related party transactions involving the reporting person are disclosed beyond the acquisition by Merck Sharp & Dohme LLC and Vol Holdings LLC, which are the acquiring entities in this transaction.

Stakeholder Impact

• Shareholders: Received cash consideration for their Ordinary Shares and ADSs as part of the acquisition.
• Employees: Implied integration into the acquiring company, potentially leading to changes in roles, benefits, or organizational structure.
• Management: Director Martin Edwards has exited his equity position, indicating the conclusion of his role with the independent entity.

Next Steps

• Verona Pharma plc will be delisted from public exchanges and integrated into Merck Sharp & Dohme LLC's operations as a wholly-owned subsidiary.

Key Dates

Keywords

Verona Pharma, VRNA, Martin Edwards, Director, SEC Form 4, Beneficial Ownership, Merger, Acquisition, Scheme of Arrangement, Merck Sharp & Dohme, Vol Holdings, Ordinary Shares, ADSs, Restricted Share Units, Share Options